Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $60 from $36 and keeps a Buy rating on the shares. The firm believes consensus is low as the company reiterated its timeline that it expects to complete enrollment on its ongoing Phase 3 EMPEROR trial for zorevunersen for Dravet syndrome in 2Q26, with data in mid-2027. The reason for the target increase is based on the new net price of $600k/year for zorevunersen.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics files automatic mixed securities shelf
- Stoke Therapeutics price target raised to $38 from $36 at Wedbush
- STOK Earnings this Week: How Will it Perform?
- Stoke Therapeutics, Biogen publish data from zorevunersen studies in NEJM
- Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP